Related Experiment Video
Updated: May 16, 2026
08:22
Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization
Published on: September 15, 2018
MicroRNAs: new players in heart failure
Vagner Oliveira-Carvalho1, Miguel Morita Fernandes da Silva, Guilherme Veiga Guimarães
1Laboratório de Insuficiência Cardíaca e Transplante, Instituto do Coração, Hospital das Clínicas da Faculdade de Medicina da USP (InCor HC-FMUSP), São Paulo, 05403-900, Brazil. vagnercarvalho@usp.br
Molecular Biology Reports
|December 18, 2012
Summary
MicroRNAs (miRNAs) are key regulators of gene expression, crucial in heart failure development and exercise adaptation. Their levels in circulation may serve as biomarkers for cardiovascular health and disease, offering therapeutic potential.
Area of Science:
- Molecular Biology
- Cardiovascular Science
- Biomarker Discovery
Background:
- MicroRNAs (miRNAs) are small non-coding RNAs regulating gene expression.
- miRNAs are implicated in the pathogenesis of heart failure and cardiac hypertrophy.
- Specific miRNAs (e.g., miR-1, miR-133, miR-208a) are cardiac-specific and linked to cardiac remodeling.
Purpose of the Study:
- To explore the role of miRNAs in heart failure.
- To investigate miRNAs as potential biomarkers for cardiovascular adaptation to exercise.
- To assess the therapeutic potential of miRNA manipulation in heart failure.
Main Methods:
- Review of current evidence on miRNA function in cardiac disease.
- Analysis of miRNA expression changes in response to physical activity.
- Evaluation of circulating miRNAs (c-miRNAs) as diagnostic and prognostic markers.
- Consideration of miRNA-based therapeutic strategies (e.g., 'miR mimics', 'antagomiRs').
Main Results:
- Certain miRNAs are upregulated in cardiac hypertrophy.
- Exercise induces rapid changes in miRNA expression.
- Circulating miRNAs show potential as biomarkers for exercise-induced cardiovascular adaptation.
- Serum miR-423-5p is being investigated for heart failure diagnosis and prognosis.
Conclusions:
- miRNAs are critical players in heart failure pathogenesis.
- Differential miRNA regulation by exercise highlights their role in cardiovascular adaptation.
- Circulating miRNAs represent promising biomarkers for cardiovascular health and disease.
- miRNA-based therapies hold significant potential for treating heart failure.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:28Mitral Regurgitation IV: Nursing Management
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...